334 related articles for article (PubMed ID: 19414362)
21. Docetaxel associated pathways in cisplatin resistant head and neck squamous cell carcinoma: a pilot study.
Yoo GH; Lin HS; Iskander AJ; Piechocki MP; Oliver J; Kewson D; Lonardo F; Tainsky MA; Kim HR; Kim H; Ensley JF
Laryngoscope; 2005 Nov; 115(11):1938-46. PubMed ID: 16319602
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of growth and telomerase activity by novel cationic ceramide analogs with high solubility in human head and neck squamous cell carcinoma cells.
Rossi MJ; Sundararaj K; Koybasi S; Phillips MS; Szulc ZM; Bielawska A; Day TA; Obeid LM; Hannun YA; Ogretmen B
Otolaryngol Head Neck Surg; 2005 Jan; 132(1):55-62. PubMed ID: 15632910
[TBL] [Abstract][Full Text] [Related]
23. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients.
Akervall J; Guo X; Qian CN; Schoumans J; Leeser B; Kort E; Cole A; Resau J; Bradford C; Carey T; Wennerberg J; Anderson H; Tennvall J; Teh BT
Clin Cancer Res; 2004 Dec; 10(24):8204-13. PubMed ID: 15623595
[TBL] [Abstract][Full Text] [Related]
24. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines.
Bradford CR; Zhu S; Ogawa H; Ogawa T; Ubell M; Narayan A; Johnson G; Wolf GT; Fisher SG; Carey TE
Head Neck; 2003 Aug; 25(8):654-61. PubMed ID: 12884349
[TBL] [Abstract][Full Text] [Related]
25. Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux) results in paradox phosphorylation of tyrosine 1173 in the receptor.
Mandic R; Rodgarkia-Dara CJ; Zhu L; Folz BJ; Bette M; Weihe E; Neubauer A; Werner JA
FEBS Lett; 2006 Sep; 580(20):4793-800. PubMed ID: 16904111
[TBL] [Abstract][Full Text] [Related]
26. Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas.
Erlich RB; Rickwood D; Coman WB; Saunders NA; Guminski A
Cancer Chemother Pharmacol; 2009 Feb; 63(3):381-9. PubMed ID: 18398612
[TBL] [Abstract][Full Text] [Related]
27. Hyaluronan-CD44 promotes phospholipase C-mediated Ca2+ signaling and cisplatin resistance in head and neck cancer.
Wang SJ; Bourguignon LY
Arch Otolaryngol Head Neck Surg; 2006 Jan; 132(1):19-24. PubMed ID: 16415424
[TBL] [Abstract][Full Text] [Related]
28. Combined gamma-irradiation and subsequent cisplatin treatment in human squamous carcinoma cell lines sensitive and resistant to cisplatin.
Caney C; Singh G; Lukka H; Rainbow AJ
Int J Radiat Biol; 2004 Apr; 80(4):291-9. PubMed ID: 15204706
[TBL] [Abstract][Full Text] [Related]
29. Neutron radiation enhances cisplatin cytotoxicity independently of apoptosis in human head and neck carcinoma cells.
Kim HE; Krug MA; Han I; Ensley J; Yoo GH; Forman JD; Kim HR
Clin Cancer Res; 2000 Oct; 6(10):4142-7. PubMed ID: 11051268
[TBL] [Abstract][Full Text] [Related]
30. Pretreatment with 5-FU enhances cisplatin cytotoxicity in head and neck squamous cell carcinoma cells.
Ijichi K; Adachi M; Hasegawa Y; Ogawa T; Nakamura H; Kudoh A; Yasui Y; Murakami S; Ishizaki K
Cancer Chemother Pharmacol; 2008 Oct; 62(5):745-52. PubMed ID: 18075740
[TBL] [Abstract][Full Text] [Related]
31. Increased cytotoxicity of squamous cell carcinoma of the head and neck by combining cisplatin with VP-16 and ciprofloxacin.
Haller J; Burgess R; Dawson D
Laryngoscope; 1993 Oct; 103(10):1081-3. PubMed ID: 8412441
[TBL] [Abstract][Full Text] [Related]
32. Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines.
Teicher BA; Cucchi CA; Lee JB; Flatow JL; Rosowsky A; Frei E
Cancer Res; 1986 Sep; 46(9):4379-83. PubMed ID: 3731096
[TBL] [Abstract][Full Text] [Related]
33. Targeting epidermal growth factor receptor in head and neck cancer.
Ford AC; Grandis JR
Head Neck; 2003 Jan; 25(1):67-73. PubMed ID: 12478546
[TBL] [Abstract][Full Text] [Related]
34. Potential role of short hairpin RNA targeting epidermal growth factor receptor in growth and sensitivity to drugs of human lung adenocarcinoma cells.
Bai L; Zhu R; Chen Z; Gao L; Zhang X; Wang X; Bai C
Biochem Pharmacol; 2006 Apr; 71(8):1265-71. PubMed ID: 16442503
[TBL] [Abstract][Full Text] [Related]
35. Mutant Nbs1 enhances cisplatin-induced DNA damage and cytotoxicity in head and neck cancer.
Tran HM; Shi G; Li G; Carney JP; O'Malley B; Li D
Otolaryngol Head Neck Surg; 2004 Oct; 131(4):477-84. PubMed ID: 15467621
[TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor (EGF) induces apoptosis in a transfected cell line expressing EGF receptor on its membrane.
Zhao X; Dai W; Zhu H; Zhang Y; Cao L; Ye Q; Lei P; Shen G
Cell Biol Int; 2006 Aug; 30(8):653-8. PubMed ID: 16750403
[TBL] [Abstract][Full Text] [Related]
37. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
[TBL] [Abstract][Full Text] [Related]
38. Fatty acid synthase is required for the proliferation of human oral squamous carcinoma cells.
Agostini M; Silva SD; Zecchin KG; Coletta RD; Jorge J; Loda M; Graner E
Oral Oncol; 2004 Aug; 40(7):728-35. PubMed ID: 15172643
[TBL] [Abstract][Full Text] [Related]
39. Profiling EGFR activity in head and neck squamous cell carcinoma by using a novel layered membrane Western blot technology.
Patel V; Ramesh A; Traicoff JL; Baibakov G; Emmert-Buck MR; Gutkind JS; Knezevic V
Oral Oncol; 2005 May; 41(5):503-8. PubMed ID: 15878755
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of cytotoxicity of cisplatin by cyclooxygenase-2 inhibitor nimesulide in head and neck cancer cell lines.
Czembirek C; Eder-Czembirek C; Erovic BM; Turhani D; Selzer E; Thurnher D
Oncol Rep; 2005 Dec; 14(6):1523-6. PubMed ID: 16273249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
